Literature DB >> 19933784

Early referral to the rheumatologist for early arthritis patients: evidence for suboptimal care. Results from the ESPOIR cohort.

Bruno Fautrel1, Mathilde Benhamou, Violaine Foltz, Nathalie Rincheval, Anne-Christine Rat, Bernard Combe, Francis Berenbaum, Pierre Bourgeois, Francis Guillemin.   

Abstract

OBJECTIVE: To assess the time to access a rheumatologist (TTAR) by early arthritis (EA) patients participating in a nationwide incidental cohort (ESPOIR) and compare it with European League Against Rheumatism (EULAR) recommendations, which recommends rapid referral, ideally within 6 weeks, to a rheumatologist for patients presenting with EA.
METHODS: Eight hundred and thirteen patients with EA were included in the cohort between 2002 and 2005. The inclusion criteria were 18-70 years old, two or more swollen joints, symptom duration from 6 weeks to 6 months and possible RA diagnosis. TTAR was defined as the time between the first synovitis and first visit to a rheumatologist. TTAR and satisfaction of the EULAR guidelines were investigated by multiple linear and logistic regressions.
RESULTS: Mean TTAR was 76 days; only 46.2% of patients were seen by a rheumatologist within the EULAR-recommended time frame. Patients' patterns of accessing medical care substantially affected access to specialized care: mean TTAR was 58 days for patients who directly scheduled an appointment with the rheumatologist and 78 days for those referred by their general practitioner (P < 0.0007). Only 57.2 and 44.5%, respectively, were able to consult a rheumatologist within 6 weeks. Multivariate analysis confirmed the significant impact of indirect access on TTAR, after adjustment for EA characteristics and medical density in the region.
CONCLUSIONS: Significant disparities were identified in the care of EA patients in terms of early access to a rheumatologist. More effort is needed to optimize the physicians' knowledge about EA and to improve the efficiency of medical networks.

Entities:  

Mesh:

Year:  2009        PMID: 19933784     DOI: 10.1093/rheumatology/kep340

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  6 in total

1.  Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort.

Authors:  Joanna Kedra; Alexandre Lafourcade; Bernard Combe; Maxime Dougados; David Hajage; Bruno Fautrel
Journal:  RMD Open       Date:  2022-05

2.  Quality-of-care standards for early arthritis clinics.

Authors:  José Andrés Román Ivorra; Juan Antonio Martínez; Pablo Lázaro; Federico Navarro; Antonio Fernandez-Nebro; Eugenio de Miguel; Estibaliz Loza; Loreto Carmona
Journal:  Rheumatol Int       Date:  2013-04-09       Impact factor: 2.631

3.  Determining early referral criteria for patients with suspected inflammatory arthritis presenting to primary care physicians: a cross-sectional study.

Authors:  Hani Almoallim; Nahid Janoudi; Suzan M Attar; Mohammed Garout; Shereen Algohary; Muhammad Irfanullah Siddiqui; Hanan Alosaimi; Ashraf Ibrahim; Amira Badokhon; Zaki Algasemi
Journal:  Open Access Rheumatol       Date:  2017-04-27

4.  Primary care challenges in diagnosing and referring patients with suspected rheumatoid arthritis: a national cross-sectional GP survey.

Authors:  Ian C Scott; Navjeet Mangat; Alex MacGregor; Karim Raza; Christian D Mallen; Samantha L Hider
Journal:  Rheumatol Adv Pract       Date:  2018-04-06

5.  Patient's access to healthcare and treatment in rheumatoid arthritis: the views of stakeholders in Portugal.

Authors:  Pedro A Laires; Rui Mesquita; Luís Veloso; Ana Paula Martins; Rui Cernadas; João Eurico Fonseca
Journal:  BMC Musculoskelet Disord       Date:  2013-09-25       Impact factor: 2.362

6.  Interface Management between General Practitioners and Rheumatologists-Results of a Survey Defining a Concept for Future Joint Recommendations.

Authors:  Rudolf Puchner; Michael Edlinger; Erich Mur; Gabriele Eberl; Manfred Herold; Peter Kufner; Antonia Puchner; Stephan E Puchner; Kurt Redlich; Alois Alkin; Klaus Machold
Journal:  PLoS One       Date:  2016-01-07       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.